On December 19, 2024, Omeros announced that its pivotal Phase 3 clinical trial of the MASP2 antibody Narsoplimab (OMS721) in...

CD19 remains a hot target in immunotherapy, driving innovation across a range of diseases. This is evidenced by recent approvals...

Domain Antigens for Antibody Discovery & Screening The antibody drug development underwent rapid progress over the past decade, with almost...

Obesity is increasingly undermining human health. Obesity, a chronic metabolic disease, has significantly impacted the health and quality of life...

What if a single cellular pathway could unlock new therapies for muscle regeneration, cancer, obesity, immune system regulation, and more?...

Recent studies have shown that various drugs, including small molecules, opioids, and antibiotics, can activate MRGPRX2 (Mas-related G-protein coupled receptor...

How VLPs are unlocking the next generation of antibody therapeutics for challenging transmembrane proteins Transmembrane proteins play crucial roles in...

What are virus-like particles (VLPs)? Virus-like particles (VLPs) are nanoparticle structures (50-300nm diameter) that mimic the organization and conformation of...

Since December 2023, there have been several positive updates about drugs targeting MSLN. On December 19th, RemeGen announced that the...

Immunotherapy is an essential option for current disease treatment. However, most patients fail to respond adequately to existing immunotherapies, such...

  On November 13, 2023, Legend Biotech officially announced that its wholly-owned subsidiary, Legend Biotech Ireland Limited, has entered into...

On December 19, 2022, the FDA approved the Phase I/IIa clinical trial application of IVS-3001, an anti-HLA-G Chimeric Antigen Receptor-T...